2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Multiple Myeloma
47
Leukemia, Myeloid, Acute
25
Recurrence
21
Lymphoma, Large B-Cell, Diffuse
13
Sarcoma
9
Lymphoma
6
Neoplasms, Plasma Cell
5
Neoplasm Metastasis
5
Glioblastoma
5
Endometrial Neoplasms
5
Ovarian Neoplasms
4
Neurofibrosarcoma
4
Neoplasms
4
Melanoma
4
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Non-Hodgkin
4
Colorectal Neoplasms
4
Triple Negative Breast Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell
3
Liposarcoma
3
Glioma
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Waldenstrom Macroglobulinemia
2
Thymoma
2
Sarcoma, Alveolar Soft Part
2
Rhabdoid Tumor
2
Interventions
Amifostine
19
Cisplatin
15
Radiotherapy
13
Etoposide
10
Cyclophosphamide
9
Carboplatin
8
Paclitaxel
7
Filgrastim
7
Drug Therapy
5
Cytarabine
5
apatinib
4
Methotrexate
4
sodium thiosulfate
3
Methylprednisolone
3
Gemcitabine
3
Docetaxel
3
sargramostim
2
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
denileukin diftitox
2
camrelizumab
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Mitoxantrone
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Drug-Related Side Effects and Adverse Reactions
×
selinexor
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled